Wu J, Zhang Q, Yang Z, Xu Y, Liu X, Wang X
J Cell Mol Med. 2024; 28(16):e70025.
PMID: 39164826
PMC: 11335579.
DOI: 10.1111/jcmm.70025.
Hong Y, Lin Y, Cheng T, Lai C, Chang Y, Huang Y
J Biomed Sci. 2024; 31(1):12.
PMID: 38254097
PMC: 10804696.
DOI: 10.1186/s12929-024-01001-0.
Lu S, Gan L, Lu T, Zhang K, Zhang J, Wu X
Theranostics. 2024; 14(1):379-391.
PMID: 38164138
PMC: 10750205.
DOI: 10.7150/thno.89495.
Zhang Q, Zhang L, Han D, Jiao X, Zheng Z, Guo K
Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi. 2023; 39(12):1168-1174.
PMID: 38129304
PMC: 11630340.
DOI: 10.3760/cma.j.cn501225-20231030-00154.
Gnesin S, Chouin N, Cherel M, Dunn S, Schaefer N, Faivre-Chauvet A
EJNMMI Res. 2023; 13(1):59.
PMID: 37314509
PMC: 10267050.
DOI: 10.1186/s13550-023-01010-4.
Inflammatory Mesenchymal Stem Cells Express Abundant Membrane-Bound and Soluble Forms of C-Type Lectin-like CD248.
Payet M, Ah-Pine F, Guillot X, Gasque P
Int J Mol Sci. 2023; 24(11).
PMID: 37298499
PMC: 10253291.
DOI: 10.3390/ijms24119546.
Comprehensive proteogenomic characterization of early duodenal cancer reveals the carcinogenesis tracks of different subtypes.
Li L, Jiang D, Liu H, Guo C, Zhao R, Zhang Q
Nat Commun. 2023; 14(1):1751.
PMID: 36991000
PMC: 10060430.
DOI: 10.1038/s41467-023-37221-5.
Soluble tumor endothelial marker 1 in heart failure with reduced ejection fraction: A pilot study.
Feng W, Chen P, Chung H, Lin Y, Li Y
Front Cardiovasc Med. 2023; 9:1015471.
PMID: 36588577
PMC: 9802008.
DOI: 10.3389/fcvm.2022.1015471.
Cd248a and Cd248b in zebrafish participate in innate immune responses.
Li X, Guo R, Yang S, Zhang X, Yin X, Teng L
Front Immunol. 2022; 13:970626.
PMID: 36119065
PMC: 9471012.
DOI: 10.3389/fimmu.2022.970626.
Molecular remodeling of adipose tissue is associated with metabolic recovery after weight loss surgery.
Bouchard-Mercier A, de Toro-Martin J, Nadeau M, Lescelleur O, Lebel S, Richard D
J Transl Med. 2022; 20(1):283.
PMID: 35739539
PMC: 9219157.
DOI: 10.1186/s12967-022-03485-6.
Tumor endothelial marker 1 is upregulated in heart after cardiac injury and participates in cardiac remodeling.
Chen P, Feng W, Tsai T, Hong Y, Lee A, Chang K
Sci Rep. 2022; 12(1):10532.
PMID: 35732643
PMC: 9218118.
DOI: 10.1038/s41598-022-14567-2.
CD248 as a bridge between angiogenesis and immunosuppression: a promising prognostic and therapeutic target for renal cell carcinoma.
Liu S, Xu C, Zhang K, Han D, Yang F, Li Y
Ann Transl Med. 2022; 9(23):1741.
PMID: 35071435
PMC: 8743697.
DOI: 10.21037/atm-21-6271.
CD248 Cancer-Associated Fibroblasts: A Novel Prognostic and Therapeutic Target for Renal Cell Carcinoma.
Xu C, Zhang K, Yang F, Zhou X, Liu S, Li Y
Front Oncol. 2021; 11:773063.
PMID: 34970489
PMC: 8712640.
DOI: 10.3389/fonc.2021.773063.
Copper-64-Labeled 1C1m-Fc, a New Tool for TEM-1 PET Imaging and Prediction of Lutetium-177-Labeled 1C1m-Fc Therapy Efficacy and Safety.
Delage J, Gnesin S, Prior J, Barbet J, Saec P, Marionneau-Lambot S
Cancers (Basel). 2021; 13(23).
PMID: 34885044
PMC: 8657097.
DOI: 10.3390/cancers13235936.
C-type lectin domain group 14 proteins in vascular biology, cancer and inflammation.
Khan K, McMurray J, Mohammed F, Bicknell R
FEBS J. 2019; 286(17):3299-3332.
PMID: 31287944
PMC: 6852297.
DOI: 10.1111/febs.14985.
CD248: A therapeutic target in cancer and fibrotic diseases.
Teicher B
Oncotarget. 2019; 10(9):993-1009.
PMID: 30847027
PMC: 6398180.
DOI: 10.18632/oncotarget.26590.
A Combined Targeted and Whole Exome Sequencing Approach Identified Novel Candidate Genes Involved in Heritable Pulmonary Arterial Hypertension.
Barozzi C, Galletti M, Tomasi L, De Fanti S, Palazzini M, Manes A
Sci Rep. 2019; 9(1):753.
PMID: 30679663
PMC: 6345742.
DOI: 10.1038/s41598-018-37277-0.
A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors.
Doi T, Aramaki T, Yasui H, Muro K, Ikeda M, Okusaka T
Invest New Drugs. 2019; 37(5):1061-1074.
PMID: 30623276
PMC: 6736902.
DOI: 10.1007/s10637-018-0713-7.
Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: a new potential target for antifibrotic therapy.
Di Benedetto P, Liakouli V, Ruscitti P, Berardicurti O, Carubbi F, Panzera N
Arthritis Res Ther. 2018; 20(1):223.
PMID: 30285896
PMC: 6235209.
DOI: 10.1186/s13075-018-1719-4.
Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma.
Capone E, Piccolo E, Fichera I, Ciufici P, Barcaroli D, Sala A
Oncotarget. 2017; 8(36):60368-60377.
PMID: 28947977
PMC: 5601145.
DOI: 10.18632/oncotarget.19499.